Abstract:Abstract Kaposi sarcoma (KS) in organ transplant recipients (OTRs) is usually due to reactivation of latent human herpes virus (HHV)-8 and is therefore seen mainly in patients from countries with a high seroprevalence of HHV-8. Far fewer cases are due to HHV-8 acquired post-transplant or donor-transmitted. Since mid-2023, NHS Blood-and-Transplant (NHS-BT) has screened donor HHV-8 serology. However, there are no recommendations for screening recipients or transplant candidates. In addition, more sensitive serology testing is not routinely available, and most centres rely on HHV-8 DNA assays. In this study, we describe clinicopathological features of OTR-KS diagnosed between 2018 and 2023 in our centre and highlight an urgent need for improved HHV-8 screening of high-risk patient groups. We reviewed clinicopathological features of OTR-KS diagnosed between January 2018 and January 2023. In total, 11 OTRs had biopsy-proven KS. The median age was 53 years range (36–69) and the median time from transplant to patient-reported onset of KS lesions was 7.5 months. Ten of 11 patients (91%) were born in sub-Saharan Africa. One patient was HIV positive. Cutaneous KS was present in all patients, there was lymph-node involvement in 5 of 11 patients (45%) and visceral involvement in 2 of 11 (18%). Serum HHV-8 DNA was positive in 9 of 11 patients (81%), although in 4 of 8 patients (50%) this was negative on at least one occasion; in 2 of 11 patients it was never positive. Viral loads did not clearly correlate with disease activity. No donors were HHV-8 positive where this information was available. The most common initial treatment intervention was modification of immunosuppression; mycophenolate mofetil was stopped in 10 of 10 patients and/or calcineurin inhibitors were switched to sirolimus in 8 of 10 OTRs. In 10 of 11 patients (91%) this was sufficient to control KS. Only one OTR required chemotherapy. Graft loss occurred in 4 of 11 cases (36%). One patient died shortly after return to dialysis following chemotherapy. We have previously published data on 16 cases of OTR-KS diagnosed in our centre between 1989 and 2018. The current series of 11 cases over the past 5 years represents a significant increase and is likely to reflect, in large part, the changing demographics of our patient population. We have demonstrated that diagnostic and predictive use of HHV-8 DNA testing has limitations: 6 of 11 patients (54%) had one or more negative tests despite positive HHV-8 immunohistochemistry on skin biopsy. Although NHS-BT now routinely screens all donors, our data highlight a significant need for routine recipient testing. We propose that routine pre/post-transplant screening with improved HHV-8 assays should be introduced, at least in patient populations at risk of latent HHV-8. Such screening has potential to allow optimized post-transplant management of HHV-8 positive OTRs and ultimately improve outcomes in OTR-KS.

Case Report: Metagenomic Next-Generation Sequencing Can Contribute to the Diagnosis and Treatment of Disseminated Visceral Kaposi Sarcoma Following Allogeneic Haematopoietic Stem Cell Transplantation

Kaposi’s Sarcoma Manifested As Lower Gastrointestinal Bleeding in a HIV/HBV-co-infected Liver Cirrhosis Patient: A Case Report

Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Clinical analysis of metagenome next-generation sequencing for diagnosing invasive fungal disease in patients with early stage of hematopoietic stem cell transplantation

Kaposi Sarcoma after Kidney Transplantation: a Case Report and Literature Review

A Case of Kaposi's Sarcoma Associated with Disseminated AIDS: The Management Challenges

BI06 The rising incidence of post-transplant Kaposi sarcoma in organ transplant recipients in a single-centre cohort: should we be routinely screening?

Kaposi Sarcoma in a Child after Fanconi Anemia-Induced Haploidentical Hematopoietic Stem Cell Transplant: A Case Report

Diagnostic Performance and Clinical Impacts of Metagenomic Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation

Case report: Difficult diagnosis of Mycobacterium tuberculosis infection in patients after allogeneic hematopoietic stem cell transplantation: two case reports and a literature review

Donor‐derived human herpesvirus 8 infection with Kaposi sarcoma and Kaposi sarcoma inflammatory cytokine syndrome in a heart transplant recipient: A case report

Coexistent Kaposi sarcoma and post-transplant lymphoproliferative disorder in the same lymph nodes after pediatric liver transplantation: A case report

Acute Leukemia Child with Ocular Kaposi's Sarcoma after Hematopoietic Stem Cell Transplantation: a Case Report and Literatures Review

Combination of metagenomic next-generation sequencing and conventional tests unraveled pathogen profiles in infected patients undergoing allogeneic hematopoietic stem cell transplantation in Jilin Province of China

S3888 Visceral Kaposi Sarcoma in a Critically Ill Patient With Ulcerative Colitis and History of Liver Transplant

Clinical Study on Cytomegalovirus-Associated Haemophagocytic Syndrome Following Allogeneic Hemotoic Stem Cell Transplantation

Application Value of Metagenomic Next-Generation Sequencing for Infectious Pathogens in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Disseminated Mycobacterium kansasii infection due to surgical site infection following allogeneic hematopoietic stem cell transplantation: A case report and literature review

Visceral Kaposi's sarcoma remission after intestinal transplant. First case report and systematic literature review

Diagnostic efficiency of metagenomic next-generation sequencing for suspected infection in allogeneic hematopoietic stem cell transplantation recipients

Rapid Progression of Kaposi’s Sarcoma Complicated with Hemophagocytic Syndrome in a Severely Immunosuppressed Patient with HIV-infection: a Case Report